Stoke Therapeutics Inc (STOK)
11.48
-0.53
(-4.41%)
USD |
NASDAQ |
May 10, 16:00
11.51
+0.03
(+0.26%)
After-Hours: 20:00
Stoke Therapeutics Research and Development Expense (Quarterly): 22.37M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 22.37M |
| December 31, 2023 | 21.78M |
| September 30, 2023 | 20.27M |
| June 30, 2023 | 20.55M |
| March 31, 2023 | 19.63M |
| December 31, 2022 | 21.06M |
| September 30, 2022 | 20.11M |
| June 30, 2022 | 18.36M |
| March 31, 2022 | 18.31M |
| December 31, 2021 | 15.80M |
| September 30, 2021 | 14.36M |
| June 30, 2021 | 14.10M |
| March 31, 2021 | 9.913M |
| Date | Value |
|---|---|
| December 31, 2020 | 8.904M |
| September 30, 2020 | 8.109M |
| June 30, 2020 | 7.968M |
| March 31, 2020 | 7.215M |
| December 31, 2019 | 7.089M |
| September 30, 2019 | 6.518M |
| June 30, 2019 | 6.023M |
| March 31, 2019 | 4.133M |
| December 31, 2018 | 3.004M |
| September 30, 2018 | 2.227M |
| June 30, 2018 | 1.888M |
| March 31, 2018 | 1.252M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.023M
Minimum
Jun 2019
22.37M
Maximum
Mar 2024
14.42M
Average
15.08M
Median
Research and Development Expense (Quarterly) Benchmarks
| NeuBase Therapeutics Inc | 0.3876M |
| iBio Inc | 1.535M |
| Actinium Pharmaceuticals Inc | 6.635M |
| Lixte Biotechnology Holdings Inc | 0.1491M |
| Fate Therapeutics Inc | 31.82M |